Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold.
about
Clinical utility, safety, and efficacy of pregabalin in the treatment of fibromyalgiaA review of the clinical utility of duloxetine in the treatment of diabetic peripheral neuropathic painBringing in health technology assessment and cost-effectiveness considerations at an early stage of drug developmentHow much does it cost to identify a critically ill child experiencing electrographic seizures?Can delivery systems use cost-effectiveness analysis to reduce healthcare costs and improve value?Electrocardiographic Screening for Prolonged QT Interval to Reduce Sudden Cardiac Death in Psychiatric Patients: A Cost-Effectiveness AnalysisCost effectiveness and value of information analyses of islet cell transplantation in the management of 'unstable' type 1 diabetes mellitusCost-effectiveness of extended release naltrexone to prevent relapse among criminal justice-involved individuals with a history of opioid use disorder.Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER-Medicare database.Modelling community-control strategies to protect hospital resources during an influenza pandemic in Ottawa, Canada.Could EEG Monitoring in Critically Ill Children Be a Cost-effective Neuroprotective Strategy?Pulmonary artery pressure-guided heart failure management: US cost-effectiveness analyses using the results of the CHAMPION clinical trialEstimating the Population Benefits and Costs of Rituximab Therapy in the United States from 1998 to 2013 Using Real-World DataThe use of Quality-Adjusted Life Years in cost-effectiveness analyses in palliative care: Mapping the debate through an integrative review.Long-term clinical benefit and cost-effectiveness of an 8-week multimodal knee osteoarthritis management program incorporating intra-articular sodium hyaluronate (Hyalgan®) injectionsScreening and Treatment for Subclinical Hypertensive Heart Disease in Emergency Department Patients With Uncontrolled Blood Pressure: A Cost-effectiveness Analysis.Economic evaluation of a population-based osteoporosis intervention for outpatients with non-traumatic non-hip fractures: the "Catch a Break" 1i [type C] FLS.Cost Effectiveness of Universal Hepatitis B Virus Screening in Patients Beginning Chemotherapy for Sarcomas or GI Stromal Tumors.Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programsCost-effectiveness of CT screening in the National Lung Screening Trial.Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses.Current status of cost utility analyses in total joint arthroplasty: a systematic review.Economic evaluation for the UK of nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreas cancer.Long-Term Cost-Effectiveness of Upper Airway Stimulation for the Treatment of Obstructive Sleep Apnea: A Model-Based Projection Based on the STAR TrialThe cost-effectiveness of surgical treatment of medial unicompartmental knee osteoarthritis in younger patients: a computer model-based evaluation.Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in Swiss patients with chronic hepatitis C.Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United StatesNext-Generation Sequencing Panels for the Diagnosis of Colorectal Cancer and Polyposis Syndromes: A Cost-Effectiveness AnalysisCost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer.Targeted Therapies Compared to Dacarbazine for Treatment of BRAF(V600E) Metastatic Melanoma: A Cost-Effectiveness AnalysisStrategies for Primary Prevention of Coronary Heart Disease Based on Risk Stratification by the ACC/AHA Lipid Guidelines, ATP III Guidelines, Coronary Calcium Scoring, and C-Reactive Protein, and a Global Treat-All Strategy: A Comparative--EffectivePartner Notification for Reduction of HIV-1 Transmission and Related Costs among Men Who Have Sex with Men: A Mathematical Modeling Study.Evaluating the quality and use of economic data in decisions about essential medicines.Cost-Effectiveness of Bronchial Thermoplasty, Omalizumab, and Standard Therapy for Moderate-to-Severe Allergic Asthma.Cost-Effectiveness of Single- Versus Generic Multiple-Tablet Regimens for Treatment of HIV-1 Infection in the United States.Modeling the Cost Effectiveness of Neuroimaging-Based Treatment of Acute Wake-Up StrokeDetecting Germline PTEN Mutations Among At-Risk Patients With Cancer: An Age- and Sex-Specific Cost-Effectiveness AnalysisCost-Effectiveness Analysis: Risk Stratification of Nonalcoholic Fatty Liver Disease (NAFLD) by the Primary Care Physician Using the NAFLD Fibrosis Score.Cost effectiveness of adherence to IDSA/ATS guidelines in elderly patients hospitalized for Community-Aquired PneumoniaAn Economic Analysis of Strategies to Control Clostridium Difficile Transmission and Infection Using an Agent-Based Simulation Model.
P2860
Q26764876-5FC30F4F-0618-437B-B95D-59AC1490DDDEQ26797234-F6C01297-F133-440C-B8E4-00E42BBEF8D7Q26866095-BCBE21C0-C9BF-4899-B4E7-1F43FD5A85DAQ27312369-B505CE41-7066-4650-B1FF-8E9A72E6976DQ28076477-A5087AD9-6741-4E88-9B27-8BAF19D171A8Q28548272-E1417650-E715-488B-B908-9A7B926CBAA1Q28600953-4E27D358-168A-42CB-8FBC-3A4467B7EC7BQ30253083-61D69EBD-B623-432B-B1AB-2B722D09C0E3Q30275646-C66F8F70-611E-4C57-8EC9-B90A22C3565FQ30403057-738F8805-12DF-42B7-AE25-53CA635A8FC8Q30685457-E53E132A-3EBA-49E7-9D02-4507E59A4DA7Q30851193-43EB13CB-AA14-4D0B-A994-1983462B2988Q31036587-D2CA0698-E356-4C7A-8014-BF2514FC6FBDQ33605471-1FF2B6E3-A193-40E4-B852-F15A47B97CFDQ33662721-0CAFEDEC-127B-4B45-AF6B-6EA9E20DD901Q33708076-60875C2C-4A27-4735-B0D1-9C0C1F09FE80Q33841955-3BD74383-0B67-498B-A8C7-860159C81579Q33872813-1C9324FC-07F9-478A-BFC4-7402E9CF38A3Q34735072-FE00D8B3-DAE7-46BD-8274-67A1E865E6AEQ35104187-F94129A1-4691-4FF6-980F-7EC6309E2177Q35197433-D7C86765-5118-4E71-854A-E7DE710D4D54Q35268110-609D59C7-0140-4506-AD3B-13C6B79D562AQ35475419-81865596-E48F-4A2E-BDBC-CC60EE8AEAAEQ35478368-AA6DA336-4337-4FD0-BA22-785438D8E1CDQ35601681-DBA332E9-5B7E-4C83-B290-D90E5802A464Q35606843-9AFB5316-F6A2-496B-B405-8A08610A1804Q35619161-DB4FD351-24C2-4AF8-A0F8-8C204CB657F4Q35708757-43A2DD5B-1465-43C8-B049-6898D871B3DDQ35754399-34FF5C7D-56F4-42AF-9AE4-16D83B577CB0Q35773340-62C95F47-2EB2-40C3-A255-BC9119C73BD3Q35793619-295C17F7-21CC-4166-88B3-4EDADAD5BAF2Q35837001-97071ADB-5E97-48EB-B492-85892F67FE9EQ35851002-979FBDC0-96ED-4C6F-AFCC-C91049DA2CB8Q35890173-977A40C1-FD7A-41FD-8E9D-1408E832DB5FQ35903617-9B3CC2A5-EC90-4B85-A57B-93F53C3E29C6Q35913167-B35E5113-DA1E-48F1-96A7-96DE2800DCDEQ35916640-1FDDD2C5-5007-40E5-80FB-6721F3967987Q35932326-B91B8F84-EDF8-4D68-9762-CCC9806096B2Q35956847-C9D5937B-C6A8-4C48-A23C-6598DEEB7458Q35975135-67DD9301-184B-472A-854D-BEBBFC9B24F4
P2860
Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold.
@en
Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold.
@nl
type
label
Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold.
@en
Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold.
@nl
prefLabel
Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold.
@en
Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold.
@nl
P356
P1476
Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold.
@en
P2093
Peter J Neumann
P304
P356
10.1056/NEJMP1405158
P407
P577
2014-08-01T00:00:00Z